Medicinal Chemistry

Primary screening studies initially generate a list of compounds with the required biological activities (‘Hits’). These Hits rarely fulfil all the criteria for a quality “tool” compound as they typically show only a moderate affinity for the target and restricted selectivity.

To become a useful tool compound, the chemical properties of the initial Hits must therefore be iteratively improved by suitable structural modification. The post-screening Hit-to-tool optimisation process is carried out by accredited chemistry partner sites in EU-OPENSCREEN ERIC Member countries and is organised as a research collaboration between the assay provider and the respective chemistry site.

Apply for funding

Currently, the European Commission offers project funding for medicinal chemistry support in our EU-OPENSCREEN ERIC partner sites through the ISIDORe project. Read more here.



Medicinal chemistry partner sites


Masaryk University (MU) – Laboratory of Organic Synthesis and Medicinal Chemistry

Dr. Kamil Paruch

Information PDF


Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) – Medicinal Chemistry

Dr. Marc Nazaré

Information PDF​​​​​​​


Latvian Institute of Organic Synthesis (LIOS)

Dr. Osvalds Pugovičs

Information PDF​​​​​​​


Institute of Biochemistry and Biophysics (IBB PAS)

Prof. Dr. Piotr Zielenkiewicz

Information PDF


University of Lisbon - Research Institute for Medicines (iMed.ULisboa)

Rui Moreira


University of Porto - Chemistry Research Centre (FCUP)

Fernanda Borges


Center for Biological Research Margarita Salas (CSIC)

Prof. Dr. Ana Martínez

Information PDF


Karolinska Institutet - Department Medical Biochemistry and Biophysics (CBCS-KI)

Anna-Lena Gustavsson


Umeå University - Chemical Biology Centre (CBCS-UmU)

Erik Chorell